title: Investigations on the ability of clenbuterol hydrochloride to reduce clinical signs and inflammation associated with equine influenza A infection.
abstract: Twenty-four Quarter Horse and Quarter Horse-cross yearlings were experimentally infected with influenza A virus (Influenza A/equine/Saskatoon/90 [H3N8]) by nebulisation. In a double blind controlled trial the horses were randomly assigned to 3 groups of 8 animals. Group 1 received a placebo, (carrier syrup), Group 2 the labelled dose and Group 3 twice the labelled dose of clenbuterol hydrochloride. All treatments were given per os b.i.d. for 10 days and started on the day of infection. The horses were monitored for clinical signs of influenza infection for 14 days. Bronchoalveolar lavages were performed 4 days prior to, and 5 and 13 days after infection. Cell counts and concentrations of prostaglandin E2 and prostaglandin F2alpha in the lavage fluid were determined. Blood samples for haematology and serology were taken 4 days before, on the day of infection, 5, 9 and 13 days after infection. All horses experienced a typical influenza infection with fever, coughing and secondary bacterial infections with mainly Actinobacillus spp. and Streptococcus spp. There was no statistically or clinically significant effect of treatment with clenbuterol hydrochloride on measured clinical or laboratory parameters within 14 days of infection.
authors.affiliation: Department of Veterinary Internal Medicine, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada.
authors.forename: S B
authors.initials: SB
authors.lastname: Kästner
authors.forename: D M
authors.initials: DM
authors.lastname: Haines
authors.forename: J
authors.initials: J
authors.lastname: Archer
authors.forename: H G
authors.initials: HG
authors.lastname: Townsend
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D018893:Bronchoalveolar Lavage / Q000662:veterinary; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology / Q000821:virology; D002976:Clenbuterol / Q000627:therapeutic use*; D003371:Cough / Q000662:veterinary; D015237:Dinoprost / Q000032:analysis; D015232:Dinoprostone / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D009980:Influenza A virus; D007958:Leukocyte Count / Q000662:veterinary; D008297:Male; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D000318:Adrenergic beta-Agonists; D015237:Dinoprost; D015232:Dinoprostone; D002976:Clenbuterol